世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

詳細検索

詳細検索

×

キーワード検索の使い方

×
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
日

抗肥満薬市場レポート：2026-2036

抗肥満薬市場レポート：2026-2036


Anti-obesity Drugs Market Report 2026-2036

内容 抗肥満薬市場レポート 2026-2036（米国貿易関税の影響を含む）：本レポートは、新たな収益源の開拓を目指す大手企業にとって、業界とその背景にある動向をより深く理解し、非常に有益な情報となるで... もっと見る

　

　

出版社
Visiongain
ヴィジョンゲイン社
出版年月
2026年1月27日
電子版価格
GBP5,150
部署ライセンス
ライセンス・価格情報／注文方法はこちら
納期
2営業日程度
ページ数
400
言語
英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

内容

抗肥満薬市場レポート 2026-2036（米国貿易関税の影響を含む）：本レポートは、新たな収益源の開拓を目指す大手企業にとって、業界とその背景にある動向をより深く理解し、非常に有益な情報となるでしょう。また、異業種への進出や、既存事業を新たな地域で拡大したい企業にも役立ちます。

デジタルヘルスケアの統合により、薬物療法による肥満管理の需要が高まっています。

デジタルヘルス・エコシステムの急速な拡大により、薬物療法による肥満管理への患者のアクセスと関与が強化されるにつれ、抗肥満薬市場は構造的な勢いを増しています。インドのAyushman Bharat Digital Missionはこの変化を象徴しており、2025年4月時点で7億6,000万件以上のAyushman Bharat Health Account（ABHA）が作成され、5億2,000万件以上の健康記録がリンクされています。この急速に拡大するデジタル基盤は、ケアの継続性を向上させ、疾患への意識を高め、薬物療法を体系的な肥満管理経路にしっかりと組み込んでいます。

遠隔医療プラットフォームとモバイルヘルスアプリケーションは、医師との日常的なやり取り、遠隔診療、体系的なフォローアップを可能にし、患者が体重、食生活、治療の遵守をより効果的にモニタリングできるようにしています。ウェアラブルデバイスとデジタルプラットフォームの統合は、主要な健康指標の継続的な追跡をサポートし、ライフスタイル介入と処方された薬物療法を連携させます。臨床医は、患者データにリアルタイムでアクセスできることで、より綿密な監視、適時の投与量の最適化、副作用の早期発見が可能になり、持続的な薬理学的介入をサポートできます。

デジタルチャネルは、肥満治療の範囲を都市部以外にも拡大させています。専門インフラが依然として限られている準都市部や地方では、バーチャル診療や電子処方箋によって抗肥満薬へのアクセスが向上しています。オンライン薬局やデジタル化された流通モデルは物流上の障壁を軽減し、統合された医療記録は医師、専門医、栄養士による連携ケアを支援しています。利便性の向上と治療の継続性は、服薬遵守率の向上と治療中断率の低下につながっています。デジタル医療サービスへの信頼が高まるにつれ、デジタルインフラは持続的な需要促進要因として台頭し、抗肥満薬療法へのアクセス、モニタリング、そして継続の方法を変革しています。

厳格な規制要件が開発コストと市場参入障壁を増大させる

肥満治療薬市場は、厳格な承認枠組みによってコンプライアンスコストが大幅に増加し、開発期間が長期化しているため、継続的な規制圧力に直面しています。主要市場の規制当局は、広範な臨床エビデンス、詳細な文書、そして優良臨床試験実施基準（GCP）の厳格な遵守を求めており、医薬品開発企業には多大な資金と技術リソースの投入が求められています。審査期間の長期化は市場参入を遅らせ、収益の見通しと投資収益率に直接的な影響を与えるだけでなく、絶えず変化する規制要件は、継続的なコンプライアンス監視と承認後の義務を通じて、業務の複雑さを増大させます。こうした状況は、規制費用が大きな参入障壁となっている中小企業や新興バイオテクノロジー企業に特に大きな影響を与えています。

米国では、食品医薬品局（FDA）が、慢性的な体重管理療法に対する包括的な安全性評価を義務付けており、これには必須の心血管アウトカム試験（CVOT）が含まれます。これらの要件は、シブトラミンやフェンフルラミンといった以前の肥満治療薬に関連した過去の安全性懸念を受けて正式に制定されました。CVOTは通常、複数年にわたる大規模な患者コホートをモニタリングするため、試験期間と開発コストが大幅に増加します。同様に、欧州医薬品庁（EMA）は厳格な長期ベネフィット・リスク評価を実施しており、ナルトレキソン／ブプロピオンの初期審査に見られるように、心血管系または精神医学的安全性データが不十分な肥満治療薬の承認を延期または却下した事例があります。日本では、医薬品医療機器総合機構（PMDA）が特定の集団を対象とした臨床データを要求しており、多くの場合、追加の地域試験が必要となり、商業化がさらに遅れます。

インドでは、規制上の制約も大きなコスト負担となっています。 1945年医薬品規則（2024年改正）に基づき、申請者は新薬の輸入に5,000米ドルの手数料を支払うとともに、中央医薬品基準管理機構（CDSCO）の広範な臨床評価要件を満たす必要があります。セマグルチドやチルゼパチドなどの治療薬の承認には、心血管系および代謝アウトカムの評価を含む包括的な安全性および有効性試験が必要であり、研究開発費が大幅に増加しています。これらの規制基準は、患者の安全性、医薬品の品質、そして公衆衛生の保護を強化する一方で、コンプライアンスコストの上昇、価格設定の柔軟性の制限、そして抗肥満薬開発におけるイノベーションのペースの抑制にもつながります。

米国の貿易関税は世界の抗肥満薬市場にどのような影響を与えるでしょうか？

米国の貿易政策の変更案は、世界の抗肥満薬市場に原材料費とサプライチェーンリスクをもたらす可能性があります。抗肥満薬分野においては、その影響は甚大となる可能性があります。米国市場で既に高価格帯となっているブランド薬や特許取得済みの治療薬は、さらなるコスト上昇に直面し、患者のアクセスと償還の柔軟性が制約される可能性があります。同時に、業界はグローバルに分散したサプライチェーン、特に中国などの国から調達される原薬に依存しているため、関税が完成品以外にも拡大した場合、さらなる脆弱性が増します。投入コストの上昇と価格圧力は、短期的な収益性を低下させ、研究開発への継続的な投資に対するインセンティブを弱める可能性があります。

同時に、政策環境は戦略的な再編を加速させる可能性があります。インドの製薬会社は、米国の貿易リスクへのエクスポージャーを軽減するため、市場多様化の取り組みを強化し、欧州、新興市場、その他の米国以外の地域へのプレゼンスを拡大する可能性が高い。多国籍企業は、製造拠点、契約製造戦略、現地化投資の見直しも検討する可能性がある。全体として、米国の潜在的な貿易関税は、世界の抗肥満薬市場全体のコスト構造、サプライチェーン構成、そして長期的なイノベーション戦略に影響を与えると予想され、将来の市場計画において政策リスクが重要な変数としてより重要になるだろう。

市場調査レポートを購入する前に、どのような質問をすべきでしょうか？

  • 抗肥満薬市場はどのように発展しているのでしょうか？
  • 抗肥満薬市場を牽引するものと抑制するものは何でしょうか？
  • 抗肥満薬市場の各サブマーケットセグメントは、予測期間中にどのように成長し、2036年にはどの程度の収益を占めるでしょうか？
  • 抗肥満薬市場の各サブマーケットの市場シェアは、2026年から2036年にかけてどのように推移するのでしょうか？
  • 2026年から2036年にかけて、市場全体を牽引する主な要因は何でしょうか？
  • 主要な抗肥満薬市場は、マクロ経済の動向に概ね追随するのでしょうか？それとも、各国の市場が他市場を上回るのでしょうか？
  • 各国の市場シェアは2036年までにどのように変化し、2036年にはどの地域が市場をリードするのでしょうか？
  • 主要プレーヤーは誰で、予測期間中の見通しはどのようなものでしょうか？
  • これらの主要企業の抗肥満薬市場におけるプロジェクトとはどのようなものでしょうか？
  • 2026年から2036年の間に、業界はどのように進化するのでしょうか？現在および今後10年間に実施されている抗肥満薬市場プロジェクトは、どのような影響を与えるのでしょうか？
  • 抗肥満薬市場をさらに拡大するために、製品の商業化の必要性は高まっているのでしょうか？
  • 抗肥満薬市場はどこに向かっているのでしょうか？そして、どうすれば市場の最前線にいられるのでしょうか？
  • 新製品・新サービスラインへの最適な投資オプションは何でしょうか？
  • 企業を新たな成長軌道に乗せ、経営幹部層を育成するための主要な見通しは何でしょうか？

これが現在、そして今後10年間の抗肥満薬市場にどのような影響を与えるかを把握する必要があります。

  • 400ページを超えるレポートには、162の表と233のグラフが掲載されており、お客様だけにご提供いたします。
  • このレポートでは、業界の主要な収益性の高い分野に焦点を当てているため、今すぐターゲットを絞ることができます。
  • 世界、地域、そして国内の売上高と成長に関する詳細な分析が含まれています。
  • 競合他社の主要な成功トレンド、変化、収益予測も示しています。

2036年までの予測とその他の分析により、事業展望が明らかになります。

  • 2036年までの収益予測に加えて、当社の最新調査では、最新の業績、成長率、市場シェアも提供しています。
  • 独自の分析に加え、事業展望と今後の展開についてもご覧いただけます。
  • 定性分析（市場動向、成長の原動力、機会、制約、課題など）、コスト構造、抗肥満薬市場価格上昇の影響、そして最近の動向についてもご確認ください。

本レポートで取り上げるセグメント

医薬品タイプ

  • 処方薬
  • OTC医薬品


分子タイプ

  • 生物学的製剤
  • 低分子医薬品


アゴニストタイプ

  • シングルアゴニスト
  • デュアルアゴニスト
  • トリアゴニスト

作用経路

  • 中枢作用型
  • 末梢作用型
  • 併用（中枢作用と末梢作用）

投与経路

  • 経口
  • 静脈内
  • 皮下

流通経路

  • 病院薬局
  • 一般薬局
  • オンライン薬局

世界市場全体とセグメントの収益予測に加えて、5 つの地域市場と 25 の主要国内市場の収益予測もご覧いただけます。

北米

  • アメリカ合衆国
  • カナダ

欧州

  • ドイツ
  • イギリス
  • フランス
  • イタリア
  • スペイン
  • ロシア
  • オランダ
  • デンマーク
  • その他の欧州地域

アジア太平洋地域

  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • 東南アジア
  • その他アジア太平洋地域地域

ラテンアメリカ

  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他のラテンアメリカ地域

中東・アフリカ地域

  • GCC
  • 南アフリカ
  • その他の中東・アフリカ地域

 

Anti-obesity Drugs Market Report 2026-2036

このレポートには、2026年から2036年までの抗肥満薬市場における主要企業のプロフィールも含まれており、これらの企業の事業のこのセグメントに重点を置いています。

レポートで紹介されている主要企業

  • Altimmune
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • CHEPLAPHARM Arzneimittel GmbH
  • Structure Therapeutics, Inc.
  • Currax
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ZEALAND PHARMA
  • Zydus Group

抗肥満薬市場の世界全体の収益は、2026年から2036年にかけて、金額ベースで2026年には220億米ドルを超えると予測されています。2036年まで力強い収益成長が見込まれます。また、最も大きな潜在能力を持つ組織を特定しています。これらの組織の能力、進捗状況、そして事業見通しを把握することで、貴社が常に優位に立つためのお手伝いをいたします。

抗肥満薬市場 2026～2036年レポートはどのように役立つでしょうか？

400ページを超えるレポートでは、以下の情報を提供しています。

  • 抗肥満薬市場 2026～2036年における2036年までの収益予測。薬剤タイプ、分子タイプ、アゴニストタイプ、作用経路、投与経路、流通チャネル別に、それぞれ世界および地域レベルで予測を掲載。業界の展望を明らかにし、最も収益性の高い投資先と収益源を見つけることができます。
  • 5つの地域市場と27の主要国市場における2036年までの収益予測。北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける抗肥満薬市場 2026～2036年までの予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアといった主要経済圏の市場予測も含まれています。
  • 既存企業と新規参入企業の見通し、そして2026年から2036年までの抗肥満薬市場に参入する主要企業19社の企業概要も掲載しています。


独自の予測に基づく定量分析と定性分析をご覧ください。当社レポートならではの情報を入手し、貴重なビジネスインテリジェンスで最新情報を入手してください。



ページTOPに戻る


目次

1 レポート概要
1.1 調査の目的
1.2 抗肥満薬市場の概要
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートで回答する主要な質問
1.6 本レポートの対象読者
1.7 調査方法
1.7.1 市場定義
1.7.2 市場評価・予測方法
1.7.3 データ検証
1.7.3.1 一次調査
1.7.3.2 二次調査
1.8 よくある質問（FAQ）
1.9 Visiongain関連レポート
1.10 Visiongainについて

2 エグゼクティブサマリー

3 市場概要
3.1 主な調査結果
3.2 市場動向
3.3 影響分析
3.3.1 市場を牽引する要因
3.3.1.1 世界的な肥満率の上昇により、革新的な抗肥満薬の需要が高まっている。
3.3.1.2 慢性疾患に対する意識の高まりにより、患者は医療による体重管理ソリューションを求めるようになります。
3.3.1.3 先進的でより安全な医薬品の発売により、採用が促進され、市場の成長が促進されます。
3.3.2 市場の抑制要因
3.3.2.1 処方箋抗肥満薬の高価格により、世界中で患者による広範な採用が制限されています。
3.3.2.2 安全性への懸念と副作用により、長期治療の遵守率が低下します。
3.3.2.3 厳格な規制当局の承認により、世界中で新しい薬理学的介入の商業化が遅れています。
3.3.3 市場機会
3.3.3.1 新興経済国は、医療投資の増加により、高い収益の可能性があります。
3.3.3.2 高齢化人口の増加により、専門的な肥満管理薬の需要が高まっています。
3.3.3.3 デジタルヘルスの統合により、パーソナライズされた肥満治療が可能になり、市場浸透が促進されます。
3.4 米国の関税：世界の抗肥満薬市場への影響は？
3.4.1 概要
3.4.2 V字回復シナリオ
3.4.2.1 なぜV字回復なのか？
3.4.2.2 関税の影響
3.4.2.3 市場動向と需要回復
3.4.2.4 政策と資金支援
3.4.2.5 回復のタイムフレーム
3.4.3 U字回復シナリオ
3.4.3.1 なぜU字回復なのか？
3.4.3.2 関税の影響
3.4.3.3 市場動向と需要回復
3.4.3.4 政策と資金支援
3.4.3.5 回復のタイムフレーム
3.4.4 L字回復シナリオ
3.4.4.1 なぜL字回復なのか？
3.4.4.2 関税の影響
3.4.4.3 市場動向と需要回復
3.4.4.4 政策および資金支援
3.4.4.5 回復までのタイムフレーム
3.4.5 顧客は短期（2025～2030年）および長期（2025～2035年）計画においてどのような戦略的考慮事項を考慮すべきか？
3.4.6 米中貿易戦争が抗肥満薬市場に与える影響
3.4.7 これらの政策変更によって、最も影響を受ける国々はどのようなプラス面とマイナス面を経験する可能性があるか？
3.4.8 世界市場の関税感応度とマージン圧力分析
3.5 ポーターのファイブフォース分析
3.5.1 サプライヤーの交渉力
3.5.2 バイヤーの交渉力
3.5.3 競争関係
3.5.4 代替品の脅威
3.5.5 新規参入の脅威
3.6 PEST分析

4 抗肥満薬市場分析：薬剤タイプ別
4.1 主な調査結果
4.2 薬剤タイプ別セグメント：市場魅力度指数
4.3 薬剤タイプ別抗肥満薬市場規模の推定と予測
4.4 処方薬
4.4.1 2026～2036年、地域別市場規模（10億米ドル）
4.4.2 地域別市場シェア、2026年および2036年（％）
4.5 一般用医薬品
4.5.1 2026～2036年、地域別市場規模（10億米ドル）
4.5.2 地域別市場シェア、2026年および2036年（％）

5 抗肥満薬市場分析：分子タイプ別
5.1 主な調査結果
5.2 分子タイプ別セグメント：市場魅力度指数
5.3 薬剤タイプ別抗肥満薬市場規模の推定と予測分子タイプ
5.4 生物製剤
5.4.1 2026～2036年、地域別市場規模（10億米ドル）
5.4.2 地域別市場シェア、2026年および2036年（％）
5.5 低分子化合物
5.5.1 2026～2036年、地域別市場規模（10億米ドル）
5.5.2 地域別市場シェア、2026年および2036年（％）

6 抗肥満薬市場分析：アゴニストタイプ別
6.1 主な調査結果
6.2 アゴニストの種類別セグメント：市場魅力度指数
6.3 抗肥満薬市場規模の推定と予測：アゴニストの種類別
6.4 シングルアゴニスト
6.4.1 2026～2036年、地域別市場規模（10億米ドル）
6.4.2 地域別市場シェア、2026年および2036年 (%)
6.5 デュアルアゴニスト
6.5.1 2026～2036年、地域別市場規模（10億米ドル）
6.5.2 地域別市場シェア、2026年および2036年 (%)
6.6 トリアゴニスト
6.6.1 2026～2036年、地域別市場規模（10億米ドル）
6.6.2 地域別市場シェア、2026年および2036年 (%)

7 抗肥満薬市場分析：作用経路別
7.1 主な知見
7.2 作用経路セグメント：市場魅力度指数
7.3 作用経路別抗肥満薬市場規模の推定と予測
7.4 中枢作用型
7.4.1 2026～2036年、地域別市場規模（10億米ドル）
7.4.2 地域別市場シェア、2026年および2036年（％）
7.5 末梢作用型
7.5.1 2026～2036年、地域別市場規模（10億米ドル）
7.5.2 地域別市場シェア、2026年および2036年（％）
7.6 複合（中枢作用と末梢作用）
7.6.1 2026～2036年、地域別市場規模（10億米ドル）
7.6.2 地域別市場シェア、 2026年および2036年 (%)

8 抗肥満薬市場分析：投与経路別
8.1 主な調査結果
8.2 投与経路セグメント：市場魅力度指数
8.3 投与経路別抗肥満薬市場規模の推定および予測
8.4 経口
8.4.1 2026～2036年、地域別市場規模（10億米ドル）
8.4.2 地域別市場シェア、2026年および2036年 (%)
8.5 静脈内
8.5.1 2026～2036年、地域別市場規模（10億米ドル）
8.5.2 地域別市場シェア、2026年および2036年 (%)
8.6 皮下
8.6.1 2026～2036年、地域別市場規模（10億米ドル）
8.6.2 地域別市場シェア、2026年および2036年（％）

9 抗肥満薬市場分析：流通チャネル別
9.1 主な調査結果
9.2 流通チャネルセグメント：市場魅力度指数
9.3 抗肥満薬市場：流通チャネル別市場規模の推定と予測
9.4 病院薬局
9.4.1 2026～2036年、地域別市場規模（10億米ドル）
9.4.2 地域別市場シェア、2026年および2036年（％）
9.5 薬局（小売薬局）
9.5.1 2026～2036年、地域別市場規模（10億米ドル）
9.5.2 地域別市場シェア、2026年および2036年（％）
9.6 オンライン薬局
9.6.1 2026～2036年、地域別市場規模（10億米ドル）
9.6.2 地域別市場シェア、2026年および2036年(%)

10 抗肥満薬市場分析：地域別
10.1 主な調査結果
10.2 地域別市場規模の推定と予測

11 北米の抗肥満薬市場分析
11.1 主な調査結果
11.2 北米抗肥満薬市場魅力度指数
11.3 北米抗肥満薬市場：国別、2026年、2031年、2036年（10億米ドル）
11.4 北米抗肥満薬市場規模推定と予測：国別
11.5 北米抗肥満薬市場規模推定と予測：薬剤タイプ別
11.6 北米抗肥満薬市場規模推定と予測：分子タイプ別
11.7 北米抗肥満薬市場規模推定と予測：アゴニストタイプ別
11.8 北米抗肥満薬市場規模推定と予測：作用経路別
11.9 北米抗肥満薬市場規模推定と予測：投与経路別
11.10 北米抗肥満薬市場規模推定と予測：流通チャネル別
11.11 米国抗肥満薬市場分析
11.12 カナダ抗肥満薬市場分析

12 欧州の抗肥満薬市場分析
12.1 主な調査結果
12.2 欧州抗肥満薬市場魅力度指数
12.3 欧州抗肥満薬市場：国別、2026年、2031年、2036年（10億米ドル）
12.4 欧州抗肥満薬市場規模推定と予測：国別
12.5 欧州抗肥満薬市場規模推定と予測：薬剤タイプ別
12.6 欧州抗肥満薬市場規模推定と予測：分子タイプ別
12.7 欧州抗肥満薬市場規模推定と予測：アゴニストタイプ別
12.8 欧州抗肥満薬市場規模推定と予測：作用経路別
12.9 欧州抗肥満薬市場規模推定と予測：投与経路別
12.10 欧州抗肥満薬市場規模推定と予測：流通チャネル別
12.11 ドイツ抗肥満薬市場分析
12.12 フランス抗肥満薬市場分析
12.13 英国抗肥満薬市場分析
12.14 イタリア抗肥満薬市場分析
12.15 スペイン抗肥満薬市場分析
12.16 ロシア抗肥満薬市場分析
12.17 その他の欧州地域抗肥満薬市場分析

13 アジア太平洋地域の抗肥満薬市場分析
13.1 主な調査結果
13.2 アジア太平洋地域抗肥満薬市場魅力度指数
13.3 アジア太平洋地域抗肥満薬市場：国別、2026年、2031年、2036年（10億米ドル）
13.4 アジア太平洋地域抗肥満薬市場規模推定と予測：国別
13.5 アジア太平洋地域抗肥満薬市場規模推定と予測：薬剤タイプ別
13.6 アジア太平洋地域抗肥満薬市場規模推定と予測：分子タイプ別
13.7 アジア太平洋地域抗肥満薬市場規模推定と予測：アゴニストタイプ別
13.8 アジア太平洋地域抗肥満薬市場規模推定と予測：作用経路別
13.9 アジア太平洋地域抗肥満薬市場規模推定と予測：投与経路別
13.10 アジア太平洋地域抗肥満薬市場規模推定と予測：流通チャネル別
13.11 日本抗肥満薬市場分析
13.12 中国抗肥満薬市場分析
13.13 インド抗肥満薬市場分析
13.14 オーストラリア抗肥満薬市場分析
13.15 韓国抗肥満薬市場分析
13.16 シンガポール肥満薬市場分析
13.17 その他のアジア太平洋地域の抗肥満薬市場分析

14 ラテンアメリカの抗肥満薬市場分析
14.1 主な調査結果
14.2 ラテンアメリカ抗肥満薬市場魅力度指数
14.3 ラテンアメリカ抗肥満薬市場：国別、2026年、2031年、2036年（10億米ドル）
14.4 ラテンアメリカ抗肥満薬市場規模推定と予測：国別
14.5 ラテンアメリカ抗肥満薬市場規模推定と予測：薬剤タイプ別
14.6 ラテンアメリカ抗肥満薬市場規模推定と予測：分子タイプ別
14.7 ラテンアメリカ抗肥満薬市場規模推定と予測：アゴニストタイプ別
14.8 ラテンアメリカ抗肥満薬市場規模推定と予測：作用経路別
14.9 ラテンアメリカ抗肥満薬市場規模推定と予測：投与経路別
14.10 ラテンアメリカ抗肥満薬市場規模推定と予測：流通チャネル別
14.11 ブラジル抗肥満薬市場分析
14.12 メキシコ抗肥満薬市場分析
14.13 アルゼンチン抗肥満薬市場分析
14.14 その他のラテンアメリカ地域抗肥満薬市場分析

15 中東・アフリカ 抗肥満薬市場分析
15.1 主な調査結果
15.2 中東・アフリカ 抗肥満薬市場魅力度指数
15.3 中東・アフリカ 抗肥満薬市場：国別、2026年、2031年、2036年（10億米ドル）
15.4 中東・アフリカ 抗肥満薬市場規模推定と予測：国別
15.5 中東・アフリカ 抗肥満薬市場規模推定と予測：薬剤タイプ別
15.6 中東・アフリカ 抗肥満薬市場規模推定と予測：分子タイプ別
15.7 中東・アフリカ 抗肥満薬市場規模推定と予測：アゴニストタイプ別
15.8 中東・アフリカ 抗肥満薬市場規模推定と予測：作用経路別
15.9 中東・アフリカ抗肥満薬市場規模推定と予測：投与経路別
15.10 中東・アフリカ抗肥満薬市場規模推定と予測：流通チャネル別
15.11 GCC抗肥満薬市場分析
15.12 南アフリカ抗肥満薬市場分析
15.13 その他中東・アフリカ地域の抗肥満薬市場分析

16 企業プロファイル
16.1 競争環境、2026年
16.2 戦略展望
16.3 アムジェン社
16.3.1 会社概要
16.3.2 会社概要
16.3.3 財務分析
16.3.3.1 純収益、2021～2024年
16.3.3.2 研究開発費、2021～2024年
16.3.3.3 地域別市場シェア、2024年
16.3.4 製品ベンチマーク
16.3.5 SWOT分析
16.3.6 戦略展望
16.4 アストラゼネカ
16.4.1 会社概要
16.4.2 会社概要
16.4.3 財務分析
16.4.3.1 純収益、2021～2024年
16.4.3.2研究開発費、2021～2024年
16.4.3.3 地域別市場シェア、2024年
16.4.3.4 事業セグメント別市場シェア、2024年
16.4.4 製品ベンチマーク
16.4.5 SWOT分析
16.4.6 戦略展望
16.5 Altimmune, Inc.
16.5.1 会社概要
16.5.2 会社概要
16.5.3 財務分析
16.5.3.1 純収益、2021～2024年
16.5.3.2 研究開発費、2021～2024年
16.5.4 製品ベンチマーク
16.5.5 SWOT分析
16.5.6 戦略展望
16.6 Bayer AG
16.6.1 会社概要
16.6.2 会社概要
16.6.3財務分析
16.6.3.1 純収益、2021～2024年
16.6.3.2 研究開発費、2021～2024年
16.6.3.3 地域別市場シェア、2024年
16.6.3.4 事業セグメント別市場シェア、2024年
16.6.4 製品ベンチマーク
16.6.5 SWOT分析
16.6.6 戦略展望
16.7 ベーリンガーインゲルハイム・インターナショナル GmbH
16.7.1 会社概要
16.7.2 会社概要
16.7.3 財務分析
16.7.3.1 純収益、2021～2024年
16.7.3.2 研究開発費、2021～2024年
16.7.3.3 地域別市場シェア、2024年
16.7.3.4 事業セグメント別市場シェア、2024年
16.7.4 製品ベンチマーク
16.7.5 SWOT分析
16.7.6 戦略展望
16.8 CHEPLAPHARM Arzneimittel GmbH
16.8.1 会社概要
16.8.2 会社概要
16.8.3 製品ベンチマーク
16.8.4 SWOT分析
16.8.5 戦略展望
16.9 Curaxx Pharmaceuticals LLC
16.9.1 会社概要
16.9.2 会社概要
16.9.3 製品ベンチマーク
16.9.4 SWOT分析
16.9.5 戦略展望
16.10 エーザイ株式会社
16.10.1 会社概要
16.10.2 会社概要
16.10.3 財務分析
16.10.3.1 純収益2021-2024
16.10.3.2 地域別市場シェア、2024年
16.10.4 製品ベンチマーク
16.10.5 SWOT分析
16.10.6 戦略展望
16.11 Lilly USA, LLC
16.11.1 会社概要
16.11.2 会社概要
16.11.3 財務分析
16.11.3.1 純収益、2021-2024年
16.11.3.2 研究開発費、2021-2024年
16.11.3.3 地域別市場シェア、2024年
16.11.3.4 事業セグメント別市場シェア、2024年
16.11.4 製品ベンチマーク
16.11.5 SWOT分析
16.11.6 戦略展望
16.12 F. ホフマン・ラ・ロシュ株式会社
16.12.1 会社概要
16.12.2 会社概要
16.12.3 財務分析
16.12.3.1 純収益（2021～2024年）
16.12.4 製品ベンチマーク
16.12.5 SWOT分析
16.12.6 戦略展望
16.13 GSK plc.
16.13.1 会社概要
16.13.2 会社概要
16.13.3 財務分析
16.13.3.1 純収益（2021～2024年）
16.13.3.2 研究開発費（2021～2024年）
16.13.3.3 地域別市場シェア（2024年）
16.13.3.4 事業セグメント別市場シェア（2024年）
16.13.4 製品ベンチマーク
16.13.5 SWOT分析
16.13.6 戦略展望
16.14 メルク社
16.14.1 会社概要
16.14.2 会社概要
16.14.3 財務分析
16.14.3.1 純収益（2021～2024年）
16.14.3.2研究開発費、2021～2024年
16.14.3.3 地域別市場シェア、2024年
16.14.3.4 事業セグメント別市場シェア、2024年
16.14.4 製品ベンチマーク
16.14.5 SWOT分析
16.14.6 戦略展望
16.15 Novo Nordisk A/S
16.15.1 会社概要
16.15.2 会社概要
16.15.3 財務分析
16.15.3.1 純収益、2021～2024年
16.15.3.2 研究開発費、2021～2024年
16.15.3.3 地域別市場シェア、2024年
16.15.3.4 事業セグメント別市場シェア、2024年
16.15.4 製品ベンチマーク
16.15.5 SWOT分析
16.15.6 戦略展望
16.16 ファイザー社
16.16.1 会社概要
16.16.2 会社概要
16.16.3 財務分析
16.16.3.1 純収益（2021～2024年）
16.16.3.2 研究開発費（2021～2024年）
16.16.3.3 地域別市場シェア（2024年）
16.16.3.4 事業セグメント別市場シェア（2024年）
16.16.4 製品ベンチマーク
16.16.5 SWOT分析
16.16.6 戦略展望
16.17 サノフィ
16.17.1 会社概要
16.17.2 会社概要
16.17.3 財務分析
16.17.3.1 純収益（2021～2024年）
16.17.3.2 研究開発費（2021～2024年）
16.17.3.3 地域別市場シェア（2024年）
16.17.3.4 事業セグメント別市場シェア（2024年）
16.17.4 製品ベンチマーク
16.17.5 SWOT分析
16.17.6 戦略展望
16.18 Structure Therapeutics, Inc.
16.18.1 会社概要
16.18.2 会社概要
16.18.3 財務分析
16.18.3.1 研究開発費（2021～2024年）
16.18.4 製品ベンチマーク
16.18.5 SWOT分析
16.18.6 戦略展望
16.19 武田薬品工業株式会社16.19.1 会社概要
16.19.2 会社概要
16.19.3 財務分析
16.19.3.1 純収益（2021～2024年）
16.19.3.2 研究開発費（2021～2024年）
16.19.3.3 地域別市場シェア（2024年）
16.19.4 製品ベンチマーク
16.19.5 SWOT分析
16.19.6 戦略展望
16.20 ジーランド・ファーマ
16.20.1 会社概要
16.20.2 会社概要
16.20.3 財務分析
16.20.3.1 純収益（2021～2024年）
16.20.3.2 研究開発費（2021～2024年）
16.20.3.3 地域別市場シェア2024
16.20.4 製品ベンチマーク
16.20.5 SWOT分析
16.20.6 戦略展望
16.21 Zydus Lifesciences Limited
16.21.1 会社概要
16.21.2 会社概要
16.21.3 財務分析
16.21.3.1 純収益（2021～2024年）
16.21.3.2 研究開発費（2021～2024年）
16.21.3.3 地域別市場シェア（2024年）
16.21.3.4 事業セグメント別市場シェア（2024年）
16.21.4 製品ベンチマーク
16.21.5 SWOT分析
16.21.6 戦略展望

17. 結論と提言
17.1 Visiongainからの結論
17.2 市場参加者への提言

ページTOPに戻る



図表リスト

List of Tables
Table 1 Anti-obesity Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Anti-obesity Drugs Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 3 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 4 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion,AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 5 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 6 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 Anti-obesity Drugs Market by Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Biologics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 12 Anti-obesity Drugs Market by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 16 Anti-obesity Drugs Market by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 21 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 23 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 25 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Anti-obesity Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 31 North America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 32 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 33 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 34 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 35 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 36 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 37 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 39 Europe Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 40 Europe Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 41 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 42 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 43 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 44 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 45 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 46 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 47 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 48 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 49 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 50 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 53 Asia Pacific Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 54 Asia Pacific Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 56 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 57 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 58 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 59 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 60 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 61 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 62 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 63 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 64 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 65 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 70 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 71 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 72 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 73 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 74 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 75 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 76 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 78 Middle East & Africa Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 79 Middle East & Africa Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 80 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 81 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 82 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 83 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 84 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 85 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 86 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 87 Strategic Outlook
Table 88 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Amgen Inc.: Product Benchmarking
Table 90 Amgen Inc.: SWOT Analysis
Table 91 Amgen Inc.: Strategic Outlook
Table 92 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AstraZeneca: Product Benchmarking
Table 94 AstraZeneca: SWOT Analysis
Table 95 AstraZeneca: Strategic Outlook
Table 96 Altimmune, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Altimmune, Inc: Product Benchmarking
Table 98 Altimmune, Inc: SWOT Analysis
Table 99 Altimmune, Inc: Strategic Outlook
Table 100 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Bayer AG: Product Benchmarking
Table 102 Bayer AG: SWOT Analysis
Table 103 Bayer AG: Strategic Outlook
Table 104 Boerhinger Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Boerhinger Ingelheim International GmbH: Product Benchmarking
Table 106 Boerhinger Ingelheim International GmbH: SWOT Analysis
Table 107 Boerhinger Ingelheim International GmbH: Strategic Outlook
Table 108 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
Table 110 CHEPLAPHARM Arzneimittel GmbH: SWOT Analysis
Table 111 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
Table 112 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Curaxx Pharmaceuticals LLC: Product Benchmarking
Table 114 Curaxx Pharmaceuticals LLC: SWOT Analysis
Table 115 Curaxx Pharmaceuticals LLC: Strategic Outlook
Table 116 Eisai Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Eisai Co., Ltd: Product Benchmarking
Table 118 Eisai Co., Ltd: SWOT Analysis
Table 119 Eisai Co., Ltd: Strategic Outlook
Table 120 Lilly USA, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Lilly USA, LLC: Product Benchmarking
Table 122 Lilly USA, LLC: SWOT Analysis
Table 123 Lilly USA, LLC: Strategic Outlook
Table 124 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 126 F. Hoffmann-La Roche Ltd: SWOT Analysis
Table 127 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 128 GSK plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 GSK plc.: Product Benchmarking
Table 130 GSK plc.: SWOT Analysis
Table 131 GSK plc.: Strategic Outlook
Table 132 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Merck & Co., Inc.: Product Benchmarking
Table 134 Merck & Co., Inc.: SWOT Analysis
Table 135 Merck & Co., Inc. .: Strategic Outlook
Table 136 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Novo Nordisk A/S: Product Benchmarking
Table 138 Novo Nordisk A/S: SWOT Analysis
Table 139 Novo Nordisk A/S: Strategic Outlook
Table 140 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Pfizer Inc.: Product Benchmarking
Table 142 Pfizer Inc.: SWOT Analysis
Table 143 Pfizer Inc.: Strategic Outlook
Table 144 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 Sanofi: Product Benchmarking
Table 146 Sanofi: SWOT Analysis
Table 147 Sanofi: Strategic Outlook
Table 148 Structure Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Structure Therapeutics, Inc.: Product Benchmarking
Table 150 Structure Therapeutics, Inc.: SWOT Analysis
Table 151 Structure Therapeutics, Inc.: Strategic Outlook
Table 152 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 154 Takeda Pharmaceutical Company Limited.: SWOT Analysis
Table 155 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 156 Zealand Pharma A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 1 Zealand Pharma A/S: Product Benchmarking
Table 157 Zealand Pharma A/S .: SWOT Analysis
Table 158 Zealand Pharma A/S : Strategic Outlook
Table 159 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 Zydus Lifesciences Limited: Product Benchmarking
Table 161 Zydus Lifesciences Limited.: SWOT Analysis
Table 162 Zydus Lifesciences: Strategic Outlook

List of Figures
Figure 1 Anti-obesity Drugs Market Segmentation
Figure 2 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 3 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
Figure 4 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
Figure 5 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
Figure 6 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 7 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 8 Anti-obesity Drugs Market Attractiveness Index by Region
Figure 9 Anti-obesity Drugs Market: Market Dynamics
Figure 10 Anti-obesity Drugs Market: Impact Analysis
Figure 11 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 12 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 13 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 14 Short Term & Long Term Planning
Figure 15 Impact of U.S. and China Trade War
Figure 16 Most Impacted Countries
Figure 17 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 18 Anti-obesity Drugs Market: Porter’s Five Forces Analysis
Figure 19 Anti-obesity Drugs Market: PEST Analysis
Figure 20 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 21 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 22 Anti-obesity Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
Figure 23 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Prescription Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 OTC Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
Figure 28 Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 29 Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026, 2031, 2036 (%)
Figure 30 Biologics Agonists Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 31 Biologics Agonists Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 32 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 33 Small Molecules Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 34 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
Figure 35 Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 36 Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026, 2031, 2036 (%)
Figure 37 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 38 Single-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 40 Dual-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 41 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 42 Tri-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 43 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
Figure 44 Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 45 Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026, 2031, 2036 (%)
Figure 46 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 47 Centrally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 48 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 49 Peripherally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 50 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%)
Figure 51 Combined (Centrally and Peripherally Acting) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 53 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 54 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 55 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 56 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 57 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 58 Intravenous Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 59 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 60 Subcutaneous Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 61 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 62 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 63 Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 64 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 65 Hospital Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 67 Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 69 Online Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 70 Anti-obesity Drugs Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
Figure 71 Anti-obesity Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 72 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %)
Figure 73 North America Anti-obesity Drugs Market Attractiveness Index
Figure 74 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 75 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 76 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 77 North America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 78 North America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 79 North America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 80 North America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 81 North America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 82 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 83 North America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 84 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 85 North America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 86 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 87 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 88 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 89 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 90 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 91 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 92 Europe Anti-obesity Drugs Market Attractiveness Index
Figure 93 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 94 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 95 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 96 Europe Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 97 Europe Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 98 Europe Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 99 Europe Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 100 Europe Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 101 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 102 Europe Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 103 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 104 Europe Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 105 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 106 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 107 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 108 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 109 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 111 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 112 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 113 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 114 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 115 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 116 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
Figure 117 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 118 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 119 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 120 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 121 Asia Pacific Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 122 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 123 Asia Pacific Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 124 Asia Pacific Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 125 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 126 Asia Pacific Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 127 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 128 Asia Pacific Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 129 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 130 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 131 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 132 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 133 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 134 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 135 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 136 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 137 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 138 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 139 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 140 Latin America Anti-obesity Drugs Market Attractiveness Index
Figure 141 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 142 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 143 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 144 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 145 Latin America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 146 Latin America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 147 Latin America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 148 Latin America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 149 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 150 Latin America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 151 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 152 Latin America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 153 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 154 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 155 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 156 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 157 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 158 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 159 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 160 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 161 Middle East & Africa Anti-obesity Drugs Market Attractiveness Index
Figure 162 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 163 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 164 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 165 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 166 Middle East & Africa Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 167 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 168 Middle East & Africa Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 169 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 170 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 171 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 172 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 173 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 174 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 175 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 176 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 177 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 178 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 179 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 180 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 181 Anti-obesity Drugs Market: Company Share/Ranking, 2026
Figure 182 Amgen Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 183 Amgen Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 184 Amgen Inc.: Regional Market Shares, 2024
Figure 185 AstraZeneca: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 186 AstraZeneca.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 187 AstraZeneca: Regional Market Shares, 2024
Figure 188 AstraZeneca: Business Segment Market Shares, 2024
Figure 189 Altimmune, Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 190 Altimmune, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 191 Bayer AG : Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 192 Bayer AG : R&D, 2021-2024 (US$ Million, AGR%)
Figure 193 Bayer AG : Regional Market Shares, 2024
Figure 194 Bayer AG : Business Segment Market Shares, 2024
Figure 195 Boehringer Ingelheim International GmbH: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 196 Boehringer Ingelheim International GmbH: R&D, 2021-2024 (US$ Million, AGR%)
Figure 197 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
Figure 198 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2024
Figure 199 Eisai Co., Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 200 Eisai Co., Ltd: Regional Market Shares, 2024
Figure 201 Lilly USA, LLC: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 202 Lilly USA, LLC: R&D, 2021-2024 (US$ Million, AGR%)
Figure 203 Lilly USA, LLC: Regional Market Shares, 2024
Figure 204 Lilly USA, LLC: Business Segment Market Shares, 2024
Figure 205 F. Hoffmann-La Roche Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 206 GSK plc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 207 GSK plc: R&D, 2021-2024 (US$ Million, AGR%)
Figure 208 GSK plc: Regional Market Shares, 2024
Figure 209 GSK plc: Business Segment Market Shares, 2024
Figure 210 Merck & Co., Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 211 Merck & Co., Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 212 Merck & Co., Inc.: Regional Market Shares, 2024
Figure 213 Merck & Co., Inc.: Business Segment Market Shares, 2024
Figure 214 Novo Nordisk A/S: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 215 Novo Nordisk A/S: R&D, 2021-2024 (US$ Million, AGR%)
Figure 216 Novo Nordisk A/S: Regional Market Shares, 2024
Figure 217 Novo Nordisk A/S.: Business Segment Market Shares, 2024
Figure 218 Pfizer Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 219 Pfizer Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 220 Pfizer Inc.: Regional Market Shares, 2024
Figure 221 Pfizer Inc.: Business Segment Market Shares, 2024
Figure 222 Sanofi: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 223 Sanofi: R&D, 2021-2024 (US$ Million, AGR%)
Figure 224 Sanofi: Regional Market Shares, 2024
Figure 225 Sanofi: Business Segment Market Shares, 2024
Figure 226 Structure Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 227 Takeda Pharmaceutical Company Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 228 Takeda Pharmaceutical Company Limited.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 229 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2024
Figure 230 Zealand Pharma A/S .: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 231 Zealand Pharma A/S : R&D, 2021-2024 (US$ Million, AGR%)
Figure 232 Zealand Pharma A/S.: Regional Market Shares, 2024
Figure 233 Zydus Lifesciences Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 234 Zydus Lifesciences Limited.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 235 Zydus Lifesciences Limited.: Regional Market Shares, 2024
Figure 236 Zydus Lifesciences Limited.: Business Segment Market Shares, 2024

 

　

ページTOPに戻る


　

Summary

Description

The Anti-obesity Drugs Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Digital Healthcare Integration Strengthens Demand for Pharmacological Obesity Management

The anti-obesity drugs market is gaining structural momentum as the rapid expansion of digital health ecosystems strengthens patient access to, and engagement with, pharmacological obesity management. India’s Ayushman Bharat Digital Mission illustrates this shift, with more than 76 crore (760 million) Ayushman Bharat Health Accounts (ABHA) created and over 52 crore (520 million) health records linked as of April 2025. This rapidly expanding digital backbone is improving continuity of care, increasing disease awareness, and embedding drug therapy more firmly within structured obesity management pathways.

Telemedicine platforms and mobile health applications are enabling routine physician interaction, remote consultations, and structured follow-up, allowing patients to monitor weight, dietary patterns, and treatment adherence more effectively. The integration of wearable devices with digital platforms supports ongoing tracking of key health indicators, aligning lifestyle interventions with prescribed drug regimens. For clinicians, real-time access to patient data enables closer supervision, timely dose optimisation, and earlier identification of adverse effects, supporting sustained pharmacological intervention.

Digital channels are also expanding the reach of obesity treatment beyond urban centres. In semi-urban and rural regions, where specialist infrastructure remains constrained, virtual consultations and e-prescriptions are improving access to anti-obesity medicines. Online pharmacies and digitally enabled distribution models are reducing logistical barriers, while integrated health records support coordinated care across physicians, specialists, and nutrition professionals. Improved convenience and treatment continuity are translating into higher compliance rates and lower therapy drop-off. As confidence in digital healthcare delivery grows, digital infrastructure is emerging as a durable demand driver, reshaping how anti-obesity drug therapies are accessed, monitored, and sustained.

Stringent Regulatory Requirements Elevate Development Costs and Market Entry Barriers

The anti-obesity drugs market faces sustained regulatory pressure, as stringent approval frameworks significantly increase compliance costs and lengthen development timelines. Regulators across major markets require extensive clinical evidence, detailed documentation, and strict adherence to Good Clinical Practice (GCP) standards, demanding substantial financial and technical resources from drug developers. Prolonged review periods delay market entry, directly affecting revenue visibility and return on investment, while continuously evolving regulatory expectations add operational complexity through ongoing compliance monitoring and post-approval obligations. These dynamics disproportionately impact smaller companies and emerging biotechs, for whom regulatory expenditure represents a major barrier to entry.

In the United States, the Food and Drug Administration mandates comprehensive safety assessments for chronic weight-management therapies, including compulsory cardiovascular outcome trials (CVOTs). These requirements were formalised following historical safety concerns associated with earlier obesity drugs such as sibutramine and fenfluramine. CVOTs typically involve large patient cohorts monitored over multiple years, materially increasing trial duration and development costs. Similarly, the European Medicines Agency applies rigorous long-term benefit–risk evaluations and has previously delayed or declined obesity drug approvals where cardiovascular or psychiatric safety data were insufficient, as seen in the initial review of naltrexone/bupropion. In Japan, the Pharmaceuticals and Medical Devices Agency requires population-specific clinical data, often necessitating additional regional trials and further delaying commercialisation.

In India, regulatory constraints also present a meaningful cost burden. Under the Drugs Rules, 1945, as amended in 2024, applicants must pay a fee of US$5,000 for the import of new drugs, alongside meeting Central Drugs Standard Control Organization (CDSCO) requirements for extensive clinical evaluation. Approvals for therapies such as semaglutide and tirzepatide involved comprehensive safety and efficacy studies, including assessments of cardiovascular and metabolic outcomes, significantly increasing research and development expenditure. While these regulatory standards reinforce patient safety, drug quality, and public health protection, they also raise compliance costs, restrict pricing flexibility, and limit the pace of innovation within the anti-obesity drug development landscape.

What would be the Impact of US Trade Tariffs on the Global Anti-obesity Drugs Market?

Proposed changes to US trade policy could introduce material cost and supply-chain risks for the global anti-obesity drugs market. For the anti-obesity drugs segment, the implications could be significant. Branded and patented therapies, which already command premium pricing in the US market, may face further cost escalation, constraining patient access and reimbursement flexibility. In parallel, the industry’s reliance on globally distributed supply chains—particularly for active pharmaceutical ingredients sourced from countries such as China—adds an additional layer of vulnerability should tariffs expand beyond finished products. Rising input costs and pricing pressure could dampen near-term profitability and weaken incentives for sustained investment in research and development.

At the same time, the policy environment may accelerate strategic realignment. Indian pharmaceutical manufacturers are likely to intensify market diversification efforts, expanding their presence across Europe, emerging markets, and other non-US regions to mitigate exposure to US trade risk. Multinational companies may also reassess manufacturing footprints, contract manufacturing strategies, and localisation investments. Overall, potential US trade tariffs are expected to influence cost structures, supply-chain configuration, and long-term innovation strategies across the global anti-obesity drugs market, reinforcing policy risk as a meaningful variable in future market planning.

What Questions Should You Ask before Buying a Market Research Report?

  • How is Anti-obesity Drugs Market evolving?
  • What is driving and restraining Anti-Obesity Drugs Market?
  • How will each Anti-Obesity Drugs Market submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each Anti-obesity Drugs Market submarket develop from 2026 to 2036?
  • What will be the main driver for the overall market from 2026 to 2036?
  • Will leading Anti-obesity Drugs Market markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Anti-Obesity Drugs Market projects for these leading companies?
  • How will the industry evolve during the period between 2026 and 2036? What are the implications of Anti-obesity Drugs
  • Market projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale Anti-obesity Drugs Market ?
  • Where is Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact Anti-obesity Drugs Market today, and over the next 10 years:

  • Our 400+ pages report provides 162 tables and 233 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them – NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2036 and other analysis reveal commercial prospects

  • In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analysis, with business outlooks and developments.
  • Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Anti-Obesity Drugs Market prices and recent developments.

Segments Covered in the Report

Drug Type

  • Prescription
  • OTC

Molecule Type

  • Biologics
  • Small Molecules

Type of Agonist

  • Single-Agonist
  • Dual-Agonist
  • Tri-Agonist

Action Pathway

  • Centrally Acting
  • Peripherally Acting
  • Combined (Centrally and Peripherally Acting)

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Denmark
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Anti-obesity Drugs Market Report 2026-2036

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2026 to 2036, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • Altimmune
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • CHEPLAPHARM Arzneimittel GmbH
  • Structure Therapeutics, Inc.
  • Currax
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ZEALAND PHARMA
  • Zydus Group

Overall world revenue for Anti-obesity Drugs Market, 2026 to 2036 in terms of value the market will surpass US$ 22.0 billion in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-obesity Drugs Market, 2026 to 2036 report help you?

In summary, our 400+ page report provides you with the following knowledge:

  • Revenue forecasts to 2036 for Anti-obesity Drugs Market, 2026 to 2036, with forecasts for drug type, Molecule Type, Type of Agonist, by Action Pathway, Route of Administration and Distribution Channel each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2036 for five regional and 27 key national markets – See forecasts for the Anti-obesity Drugs Market, 2026 to 2036 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market – including company profiles for 19 of the major companies involved in the Anti-obesity Drugs Market, 2026 to 2036.

Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

 

 

 



ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Anti-obesity Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rising global obesity prevalence increases demand for innovative anti-obesity drugs.
3.3.1.2 Expanding chronic disease awareness drives patients toward medical weight management solutions.
3.3.1.3 Launch of advanced, safer drugs boosts adoption and commercial market growth.
3.3.2 Market Restraining Factors
3.3.2.1 High pricing of prescription anti-obesity drugs limits widespread patient adoption globally.
3.3.2.2 Safety concerns and adverse effects reduce long-term therapy adherence rates.
3.3.2.3 Stringent regulatory approvals delay the commercialization of new pharmacological interventions worldwide.
3.3.3 Market Opportunities
3.3.3.1 Emerging economies present high revenue potential due to rising healthcare investments.
3.3.3.2 Growing geriatric population creates demand for specialized obesity management medications.
3.3.3.3 Digital health integration enables personalized obesity treatment, increasing market penetration.
3.4 U.S. Tariffs: What’s the Impact on Global Anti-obesity Drugs Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.2.5 Timeframe for Recovery
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Market Dynamics and Demand Recovery
3.4.3.4 Policy and Funding Support
3.4.3.5 Timeframe for Recovery
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025–2030) and Long-term (2025–2035) Planning?
3.4.6 Impact of U.S. and China Trade War on Anti-obesity Drugs Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type
4.1 Key Findings
4.2 Drug Type Segment: Market Attractiveness Index
4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
4.4 Prescription
4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 OTC
4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.2 Market Share by Region, 2026 & 2036 (%)

5 Anti-obesity Drugs Market Analysis by Molecule Type
5.1 Key Findings
5.2 Molecule Type Segment: Market Attractiveness Index
5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
5.4 Biologics
5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Small Molecules
5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Anti-obesity Drugs Market Analysis by Type of Agonist
6.1 Key Findings
6.2 Type of Agonist Segment: Market Attractiveness Index
6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
6.4 Single-Agonist
6.4.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Dual-Agonist
6.5.1 Market Size by Region, 2026-2036 (US$ Billion)
6.5.2 Market Share by Region, 2026 & 2036 (%)
6.6 Tri-Agonist
6.6.1 Market Size by Region, 2026-2036 (US$ Billion)
6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Anti-obesity Drugs Market Analysis by Action Pathway
7.1 Key Findings
7.2 Action Pathway Segment: Market Attractiveness Index
7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
7.4 Centrally Acting
7.4.1 Market Size by Region, 2026-2036 (US$ Billion)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Peripherally Acting
7.5.1 Market Size by Region, 2026-2036 (US$ Billion)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Combined (Centrally and Peripherally Acting)
7.6.1 Market Size by Region, 2026-2036 (US$ Billion)
7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Anti-obesity Drugs Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
8.4 Oral
8.4.1 Market Size by Region, 2026-2036 (US$ Billion)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Intravenous
8.5.1 Market Size by Region, 2026-2036 (US$ Billion)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Subcutaneous
8.6.1 Market Size by Region, 2026-2036 (US$ Billion)
8.6.2 Market Share by Region, 2026 & 2036 (%)

9 Anti-obesity Drugs Market Analysis by Distribution Channel
9.1 Key Findings
9.2 Distribution Channel Segment: Market Attractiveness Index
9.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
9.4 Hospital Pharmacies
9.4.1 Market Size by Region, 2026-2036 (US$ Billion)
9.4.2 Market Share by Region, 2026 & 2036 (%)
9.5 Retail Pharmacies
9.5.1 Market Size by Region, 2026-2036 (US$ Billion)
9.5.2 Market Share by Region, 2026 & 2036 (%)
9.6 Online Pharmacies
9.6.1 Market Size by Region, 2026-2036 (US$ Billion)
9.6.2 Market Share by Region, 2026 & 2036 (%)

10 Anti-obesity Drugs Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Anti-obesity Drugs Market Analysis
11.1 Key Findings
11.2 North America Anti-obesity Drugs Market Attractiveness Index
11.3 North America Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
11.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
11.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
11.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
11.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
11.9 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
11.10 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
11.11 U.S. Anti-obesity Drugs Market Analysis
11.12 Canada Anti-obesity Drugs Market Analysis

12 Europe Anti-obesity Drugs Market Analysis
12.1 Key Findings
12.2 Europe Anti-obesity Drugs Market Attractiveness Index
12.3 Europe Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
12.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
12.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
12.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
12.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
12.9 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
12.10 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
12.11 Germany Anti-obesity Drugs Market Analysis
12.12 France Anti-obesity Drugs Market Analysis
12.13 UK Anti-obesity Drugs Market Analysis
12.14 Italy Anti-obesity Drugs Market Analysis
12.15 Spain Anti-obesity Drugs Market Analysis
12.16 Russia Anti-obesity Drugs Market Analysis
12.17 Rest of Europe Anti-obesity Drugs Market Analysis

13 Asia Pacific Anti-obesity Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
13.3 Asia Pacific Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
13.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
13.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
13.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
13.9 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
13.10 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
13.11 Japan Anti-obesity Drugs Market Analysis
13.12 China Anti-obesity Drugs Market Analysis
13.13 India Anti-obesity Drugs Market Analysis
13.14 Australia Anti-obesity Drugs Market Analysis
13.15 South Korea Anti-obesity Drugs Market Analysis
13.16 Singapore Anti-obesity Drugs Market Analysis
13.17 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

14 Latin America Anti-obesity Drugs Market Analysis
14.1 Key Findings
14.2 Latin America Anti-obesity Drugs Market Attractiveness Index
14.3 Latin America Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
14.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
14.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
14.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
14.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
14.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
14.9 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
14.10 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
14.11 Brazil Anti-obesity Drugs Market Analysis
14.12 Mexico Anti-obesity Drugs Market Analysis
14.13 Argentina Anti-obesity Drugs Market Analysis
14.14 Rest of Latin America Anti-obesity Drugs Market Analysis

15 Middle East & Africa Anti-obesity Drugs Market Analysis
15.1 Key Findings
15.2 Middle East & Africa Anti-obesity Drugs Market Attractiveness Index
15.3 Middle East & Africa Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
15.4 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Country
15.5 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
15.6 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
15.7 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
15.8 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
15.9 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
15.10 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
15.11 GCC Anti-obesity Drugs Market Analysis
15.12 South Africa Anti-obesity Drugs Market Analysis
15.13 Rest of MEA Anti-obesity Drugs Market Analysis

16 Company Profiles
16.1 Competitive Landscape, 2026
16.2 Strategic Outlook
16.3 Amgen Inc.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2021-2024
16.3.3.2 R&D, 2021-2024
16.3.3.3 Regional Market Shares, 2024
16.3.4 Product Benchmarking
16.3.5 SWOT Analysis
16.3.6 Strategic Outlook
16.4 AstraZeneca
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2021-2024
16.4.3.2 R&D, 2021-2024
16.4.3.3 Regional Market Shares, 2024
16.4.3.4 Business Segment Market Shares, 2024
16.4.4 Product Benchmarking
16.4.5 SWOT Analysis
16.4.6 Strategic Outlook
16.5 Altimmune, Inc
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2021-2024
16.5.3.2 R&D, 2021-2024
16.5.4 Product Benchmarking
16.5.5 SWOT Analysis
16.5.6 Strategic Outlook
16.6 Bayer AG
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2021-2024
16.6.3.2 R&D, 2021-2024
16.6.3.3 Regional Market Shares, 2024
16.6.3.4 Business Segment Market Shares, 2024
16.6.4 Product Benchmarking
16.6.5 SWOT Analysis
16.6.6 Strategic Outlook
16.7 Boehringer Ingelheim International GmbH
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2021-2024
16.7.3.2 R&D, 2021-2024
16.7.3.3 Regional Market Shares, 2024
16.7.3.4 Business Segment Market Shares, 2024
16.7.4 Product Benchmarking
16.7.5 SWOT Analysis
16.7.6 Strategic Outlook
16.8 CHEPLAPHARM Arzneimittel GmbH
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Product Benchmarking
16.8.4 SWOT Analysis
16.8.5 Strategic Outlook
16.9 Curaxx Pharmaceuticals LLC
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Product Benchmarking
16.9.4 SWOT Analysis
16.9.5 Strategic Outlook
16.10 Eisai Co., Ltd.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2021-2024
16.10.3.2 Regional Market Shares, 2024
16.10.4 Product Benchmarking
16.10.5 SWOT Analysis
16.10.6 Strategic Outlook
16.11 Lilly USA, LLC
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2021-2024
16.11.3.2 R&D, 2021-2024
16.11.3.3 Regional Market Shares, 2024
16.11.3.4 Business Segment Market Shares, 2024
16.11.4 Product Benchmarking
16.11.5 SWOT Analysis
16.11.6 Strategic Outlook
16.12 F. Hoffmann-La Roche Ltd.
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.3.1 Net Revenue, 2021-2024
16.12.4 Product Benchmarking
16.12.5 SWOT Analysis
16.12.6 Strategic Outlook
16.13 GSK plc.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2021-2024
16.13.3.2 R&D, 2021-2024
16.13.3.3 Regional Market Shares, 2024
16.13.3.4 Business Segment Market Shares, 2024
16.13.4 Product Benchmarking
16.13.5 SWOT Analysis
16.13.6 Strategic Outlook
16.14 Merck & Co., Inc.
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2021-2024
16.14.3.2 R&D, 2021-2024
16.14.3.3 Regional Market Shares, 2024
16.14.3.4 Business Segment Market Shares, 2024
16.14.4 Product Benchmarking
16.14.5 SWOT Analysis
16.14.6 Strategic Outlook
16.15 Novo Nordisk A/S
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2021-2024
16.15.3.2 R&D, 2021-2024
16.15.3.3 Regional Market Shares, 2024
16.15.3.4 Business Segment Market Shares, 2024
16.15.4 Product Benchmarking
16.15.5 SWOT Analysis
16.15.6 Strategic Outlook
16.16 Pfizer Inc.
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2021-2024
16.16.3.2 R&D, 2021-2024
16.16.3.3 Regional Market Shares, 2024
16.16.3.4 Business Segment Market Shares, 2024
16.16.4 Product Benchmarking
16.16.5 SWOT Analysis
16.16.6 Strategic Outlook
16.17 Sanofi
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Financial Analysis
16.17.3.1 Net Revenue, 2021-2024
16.17.3.2 R&D, 2021-2024
16.17.3.3 Regional Market Shares, 2024
16.17.3.4 Business Segment Market Shares, 2024
16.17.4 Product Benchmarking
16.17.5 SWOT Analysis
16.17.6 Strategic Outlook
16.18 Structure Therapeutics, Inc.
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 R&D, 2021-2024
16.18.4 Product Benchmarking
16.18.5 SWOT Analysis
16.18.6 Strategic Outlook
16.19 Takeda Pharmaceutical Company Limited.
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Financial Analysis
16.19.3.1 Net Revenue, 2021-2024
16.19.3.2 R&D, 2021-2024
16.19.3.3 Regional Market Shares, 2024
16.19.4 Product Benchmarking
16.19.5 SWOT Analysis
16.19.6 Strategic Outlook
16.20 Zealand Pharma
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Financial Analysis
16.20.3.1 Net Revenue, 2021-2024
16.20.3.2 R&D, 2021-2024
16.20.3.3 Regional Market Shares, 2024
16.20.4 Product Benchmarking
16.20.5 SWOT Analysis
16.20.6 Strategic Outlook
16.21 Zydus Lifesciences Limited
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Financial Analysis
16.21.3.1 Net Revenue, 2021-2024
16.21.3.2 R&D, 2021-2024
16.21.3.3 Regional Market Shares, 2024
16.21.3.4 Business Segment Market Shares, 2024
16.21.4 Product Benchmarking
16.21.5 SWOT Analysis
16.21.6 Strategic Outlook

17. Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

 

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1 Anti-obesity Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Anti-obesity Drugs Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 3 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 4 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion,AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 5 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 6 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 Anti-obesity Drugs Market by Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Biologics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 12 Anti-obesity Drugs Market by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 16 Anti-obesity Drugs Market by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 21 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 23 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 25 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Anti-obesity Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 31 North America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 32 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 33 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 34 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 35 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 36 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 37 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 39 Europe Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 40 Europe Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 41 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 42 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 43 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 44 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 45 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 46 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 47 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 48 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 49 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 50 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 53 Asia Pacific Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 54 Asia Pacific Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 55 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 56 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 57 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 58 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 59 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 60 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 61 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 62 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 63 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 64 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 65 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 67 Latin America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 68 Latin America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 69 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 70 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 71 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 72 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 73 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 74 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 75 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 76 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 78 Middle East & Africa Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 79 Middle East & Africa Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 80 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 81 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 82 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 83 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
Table 84 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 85 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 86 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 87 Strategic Outlook
Table 88 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Amgen Inc.: Product Benchmarking
Table 90 Amgen Inc.: SWOT Analysis
Table 91 Amgen Inc.: Strategic Outlook
Table 92 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AstraZeneca: Product Benchmarking
Table 94 AstraZeneca: SWOT Analysis
Table 95 AstraZeneca: Strategic Outlook
Table 96 Altimmune, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Altimmune, Inc: Product Benchmarking
Table 98 Altimmune, Inc: SWOT Analysis
Table 99 Altimmune, Inc: Strategic Outlook
Table 100 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Bayer AG: Product Benchmarking
Table 102 Bayer AG: SWOT Analysis
Table 103 Bayer AG: Strategic Outlook
Table 104 Boerhinger Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Boerhinger Ingelheim International GmbH: Product Benchmarking
Table 106 Boerhinger Ingelheim International GmbH: SWOT Analysis
Table 107 Boerhinger Ingelheim International GmbH: Strategic Outlook
Table 108 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
Table 110 CHEPLAPHARM Arzneimittel GmbH: SWOT Analysis
Table 111 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
Table 112 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Curaxx Pharmaceuticals LLC: Product Benchmarking
Table 114 Curaxx Pharmaceuticals LLC: SWOT Analysis
Table 115 Curaxx Pharmaceuticals LLC: Strategic Outlook
Table 116 Eisai Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Eisai Co., Ltd: Product Benchmarking
Table 118 Eisai Co., Ltd: SWOT Analysis
Table 119 Eisai Co., Ltd: Strategic Outlook
Table 120 Lilly USA, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Lilly USA, LLC: Product Benchmarking
Table 122 Lilly USA, LLC: SWOT Analysis
Table 123 Lilly USA, LLC: Strategic Outlook
Table 124 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 126 F. Hoffmann-La Roche Ltd: SWOT Analysis
Table 127 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 128 GSK plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 GSK plc.: Product Benchmarking
Table 130 GSK plc.: SWOT Analysis
Table 131 GSK plc.: Strategic Outlook
Table 132 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Merck & Co., Inc.: Product Benchmarking
Table 134 Merck & Co., Inc.: SWOT Analysis
Table 135 Merck & Co., Inc. .: Strategic Outlook
Table 136 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Novo Nordisk A/S: Product Benchmarking
Table 138 Novo Nordisk A/S: SWOT Analysis
Table 139 Novo Nordisk A/S: Strategic Outlook
Table 140 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 141 Pfizer Inc.: Product Benchmarking
Table 142 Pfizer Inc.: SWOT Analysis
Table 143 Pfizer Inc.: Strategic Outlook
Table 144 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 Sanofi: Product Benchmarking
Table 146 Sanofi: SWOT Analysis
Table 147 Sanofi: Strategic Outlook
Table 148 Structure Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Structure Therapeutics, Inc.: Product Benchmarking
Table 150 Structure Therapeutics, Inc.: SWOT Analysis
Table 151 Structure Therapeutics, Inc.: Strategic Outlook
Table 152 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 154 Takeda Pharmaceutical Company Limited.: SWOT Analysis
Table 155 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 156 Zealand Pharma A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 1 Zealand Pharma A/S: Product Benchmarking
Table 157 Zealand Pharma A/S .: SWOT Analysis
Table 158 Zealand Pharma A/S : Strategic Outlook
Table 159 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 Zydus Lifesciences Limited: Product Benchmarking
Table 161 Zydus Lifesciences Limited.: SWOT Analysis
Table 162 Zydus Lifesciences: Strategic Outlook

List of Figures
Figure 1 Anti-obesity Drugs Market Segmentation
Figure 2 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 3 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
Figure 4 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
Figure 5 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
Figure 6 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 7 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 8 Anti-obesity Drugs Market Attractiveness Index by Region
Figure 9 Anti-obesity Drugs Market: Market Dynamics
Figure 10 Anti-obesity Drugs Market: Impact Analysis
Figure 11 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 12 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 13 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 14 Short Term & Long Term Planning
Figure 15 Impact of U.S. and China Trade War
Figure 16 Most Impacted Countries
Figure 17 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 18 Anti-obesity Drugs Market: Porter’s Five Forces Analysis
Figure 19 Anti-obesity Drugs Market: PEST Analysis
Figure 20 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
Figure 21 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 22 Anti-obesity Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
Figure 23 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Prescription Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 OTC Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
Figure 28 Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 29 Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026, 2031, 2036 (%)
Figure 30 Biologics Agonists Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 31 Biologics Agonists Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 32 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 33 Small Molecules Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 34 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
Figure 35 Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 36 Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026, 2031, 2036 (%)
Figure 37 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 38 Single-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 40 Dual-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 41 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 42 Tri-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 43 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
Figure 44 Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 45 Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026, 2031, 2036 (%)
Figure 46 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 47 Centrally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 48 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 49 Peripherally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 50 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%)
Figure 51 Combined (Centrally and Peripherally Acting) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
Figure 53 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 54 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 55 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 56 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 57 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 58 Intravenous Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 59 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 60 Subcutaneous Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 61 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
Figure 62 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 63 Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 64 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 65 Hospital Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 67 Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 69 Online Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 70 Anti-obesity Drugs Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
Figure 71 Anti-obesity Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 72 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %)
Figure 73 North America Anti-obesity Drugs Market Attractiveness Index
Figure 74 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 75 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 76 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 77 North America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 78 North America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 79 North America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 80 North America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 81 North America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 82 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 83 North America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 84 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 85 North America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 86 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 87 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 88 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 89 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 90 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 91 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 92 Europe Anti-obesity Drugs Market Attractiveness Index
Figure 93 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 94 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 95 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 96 Europe Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 97 Europe Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 98 Europe Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 99 Europe Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 100 Europe Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 101 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 102 Europe Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 103 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 104 Europe Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 105 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 106 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 107 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 108 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 109 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 111 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 112 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 113 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 114 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 115 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 116 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
Figure 117 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 118 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 119 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 120 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 121 Asia Pacific Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 122 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 123 Asia Pacific Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 124 Asia Pacific Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 125 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 126 Asia Pacific Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 127 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 128 Asia Pacific Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 129 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 130 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 131 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 132 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 133 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 134 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 135 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 136 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 137 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 138 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 139 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 140 Latin America Anti-obesity Drugs Market Attractiveness Index
Figure 141 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 142 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 143 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 144 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 145 Latin America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 146 Latin America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 147 Latin America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 148 Latin America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 149 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 150 Latin America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 151 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 152 Latin America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 153 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 154 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 155 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 156 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 157 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 158 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 159 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 160 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 161 Middle East & Africa Anti-obesity Drugs Market Attractiveness Index
Figure 162 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 163 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 164 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 165 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
Figure 166 Middle East & Africa Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
Figure 167 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
Figure 168 Middle East & Africa Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
Figure 169 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
Figure 170 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
Figure 171 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
Figure 172 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
Figure 173 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
Figure 174 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 175 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 176 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 177 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 178 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 179 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 180 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 181 Anti-obesity Drugs Market: Company Share/Ranking, 2026
Figure 182 Amgen Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 183 Amgen Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 184 Amgen Inc.: Regional Market Shares, 2024
Figure 185 AstraZeneca: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 186 AstraZeneca.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 187 AstraZeneca: Regional Market Shares, 2024
Figure 188 AstraZeneca: Business Segment Market Shares, 2024
Figure 189 Altimmune, Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 190 Altimmune, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 191 Bayer AG : Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 192 Bayer AG : R&D, 2021-2024 (US$ Million, AGR%)
Figure 193 Bayer AG : Regional Market Shares, 2024
Figure 194 Bayer AG : Business Segment Market Shares, 2024
Figure 195 Boehringer Ingelheim International GmbH: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 196 Boehringer Ingelheim International GmbH: R&D, 2021-2024 (US$ Million, AGR%)
Figure 197 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
Figure 198 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2024
Figure 199 Eisai Co., Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 200 Eisai Co., Ltd: Regional Market Shares, 2024
Figure 201 Lilly USA, LLC: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 202 Lilly USA, LLC: R&D, 2021-2024 (US$ Million, AGR%)
Figure 203 Lilly USA, LLC: Regional Market Shares, 2024
Figure 204 Lilly USA, LLC: Business Segment Market Shares, 2024
Figure 205 F. Hoffmann-La Roche Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 206 GSK plc: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 207 GSK plc: R&D, 2021-2024 (US$ Million, AGR%)
Figure 208 GSK plc: Regional Market Shares, 2024
Figure 209 GSK plc: Business Segment Market Shares, 2024
Figure 210 Merck & Co., Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 211 Merck & Co., Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 212 Merck & Co., Inc.: Regional Market Shares, 2024
Figure 213 Merck & Co., Inc.: Business Segment Market Shares, 2024
Figure 214 Novo Nordisk A/S: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 215 Novo Nordisk A/S: R&D, 2021-2024 (US$ Million, AGR%)
Figure 216 Novo Nordisk A/S: Regional Market Shares, 2024
Figure 217 Novo Nordisk A/S.: Business Segment Market Shares, 2024
Figure 218 Pfizer Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 219 Pfizer Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 220 Pfizer Inc.: Regional Market Shares, 2024
Figure 221 Pfizer Inc.: Business Segment Market Shares, 2024
Figure 222 Sanofi: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 223 Sanofi: R&D, 2021-2024 (US$ Million, AGR%)
Figure 224 Sanofi: Regional Market Shares, 2024
Figure 225 Sanofi: Business Segment Market Shares, 2024
Figure 226 Structure Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 227 Takeda Pharmaceutical Company Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 228 Takeda Pharmaceutical Company Limited.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 229 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2024
Figure 230 Zealand Pharma A/S .: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 231 Zealand Pharma A/S : R&D, 2021-2024 (US$ Million, AGR%)
Figure 232 Zealand Pharma A/S.: Regional Market Shares, 2024
Figure 233 Zydus Lifesciences Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 234 Zydus Lifesciences Limited.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 235 Zydus Lifesciences Limited.: Regional Market Shares, 2024
Figure 236 Zydus Lifesciences Limited.: Business Segment Market Shares, 2024

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

Visiongain社の ケミカル・材料分野 での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Visiongain社はどのような調査会社ですか?


英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

当社ご利用のメリット
  1. ① お探しの情報に合わせてレポートをご紹介
  2. ② レポートで不足している情報はカスタマイズで対応可能
  3. ③ 特許情報、海外の法規制の取り組みなどディープな調査も対応可能
  4. ④ 円貨で請求書払い＆万全のアフターフォロー

 

2026/03/09　10:26

159.71 円

184.25 円

215.13 円

ページTOPに戻る

株式会社 データリソース　Data Resource, Inc.
東京都千代田区丸の内3-3-1 新東京ビル4F 430


A member of CORSS Business Producers Inc.
データリソースは2025年5月より
CROSS Business Producers株式会社 の100%子会社になりました。

電話：03-3582-2531
FAX：03-6551-2556
Eメール：office@dri.co.jp

会社概要 FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2025　DATA RESOURCE, Inc. ALL RIGHTS RESERVED.